The HAT Inhibitor ISOX‐DUAL Diminishes Ischemic Areas in a Mouse Model of Oxygen‐Induced Retinopathy
Authors:
Open Access
- 7 February 2025
- journal article
- Published by Wiley in Genes to Cells
- Vol. 30 (2) , e13196
Abstract
Retinal ischemic disease results in significant visual impairment due to the development of fragile and disorganized, pathologically running blood vessels in the eye. Currently, the mainstay treatment for this disease is the intravitreal administration of anti‐VEGF drugs targeting vascular endothelial growth factor (VEGF), which induces angiogenesis. However, current anti‐VEGF drugs do not diminish the ischemic areas that lead to angiogenesis, making fundamental treatment challenging. Since retinopathy is an acquired disease caused by hypoxic stimulation from ischemia, we paid particular attention to histone acetylases. We conducted a drug screening experiment using a mouse model of oxygen‐induced retinopathy (OIR), which replicates retinal ischemic disease, through the intraperitoneal administration of 17 distinct inhibitors targeting histone acetyltransferases (HAT). The results indicated that, among the 17 inhibitors, only ISOX‐DUAL decreased neovascularization and ischemic regions. Furthermore, microarray analysis was conducted on the drug‐treated samples to refine genes altered by the administration of ISOX‐DUAL. There were 21 genes associated with angiogenesis, including Angpt2, Hmox1, Edn1, and Serpine1, exhibited upregulation in OIR mice and downregulation following treatment with ISOX‐DUAL. Furthermore, STRING analysis confirmed that the aforementioned four genes are downstream factors of hypoxia‐inducible factors and are assumed to be important factors in retinal ischemic diseases.Keywords
This publication has 51 references indexed in Scilit:
- Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesisNature Protocols, 2009
- Histone acetyltransferase inhibitors and preclinical studiesExpert Opinion on Therapeutic Patents, 2009
- Inflammation induced by photocoagulation laser is minimized by copper chelatorsLasers in Medical Science, 2008
- Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusionBritish Journal of Ophthalmology, 2008
- Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective studyBritish Journal of Ophthalmology, 2008
- Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathyJournal of Clinical Investigation, 2006
- Vascular Endothelial Growth Factor: Basic Science and Clinical ProgressEndocrine Reviews, 2004
- The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiologyActa Ophthalmologica Scandinavica, 2001
- Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1Genes & Development, 1999
- Oxygen-induced retinopathy in the mouse.1994